Drug – bio-affecting and body treating compositions – Extract – body fluid – or cellular material of undetermined... – Tissue – other than lymphoid tissue
Reexamination Certificate
1999-08-13
2003-04-01
Wehbe', Anne M. (Department: 1632)
Drug, bio-affecting and body treating compositions
Extract, body fluid, or cellular material of undetermined...
Tissue, other than lymphoid tissue
C424S572000, C424S422000, C424S424000, C424S093100, C536S023100, C514S04400A, C435S320100, C435S325000
Reexamination Certificate
active
06541036
ABSTRACT:
FIELD OF THE INVENTION
The present application is directed to inducing resistance to or regression of tumor growth in humans using implanted diffusion chambers containing tumor cells treated with oligonucleotides directed to IGF-IR.
BACKGROUND OF THE INVENTION
Traditional methods of treating tumors in mammals include procedures such as, for example, surgical removal of the tumor, injection or implantation of toxic treatments or syngeneic tissue samples, chemotherapy, and irradiation. The ultimate goal of each of these procedures is to reduce the growth of existing tumors, preferably abrogating tumor growth to the point of complete regression, and/or to induce resistance to future tumor growth. These procedures have numerous effects on tumor cells, as well as on non-tumor cells.
Tumors and other neoplastic tissues are known to undergo apoptosis spontaneously or in response to treatment. Examples include several types of leukemia, non-Hodgkin's lymphoma, prostate tumor, pancreatic cancer, basal and squamous cell carcinoma, mammary tumor, breast cancer, and fat pad sarcoma. Several anti-cancer drugs have been shown to induce apoptosis in target cells. Buttyan, et al.,
Mol. Cell. Biol.,
1989, 9, 3473-3481; Kaufmann,
Cancer Res.,
1989, 49, 5870-5878; and Barry, et al.,
Biochem. Pharmacol.,
1990, 40, 2353-2362, all of which are incorporated herein by reference in their entirety. Certain mildly adverse conditions can result in the injured cell dying by programmed cell death, including hyperthermia, hypothermia, ischemia, and exposure to irradiation, toxins, and chemicals. It should be noted that many of these treatments will also result in necrosis at higher doses, suggesting that mild injury to a cell might induce cell suicide, perhaps to prevent the inheritance of a mutation, while exposure to severe conditions leads directly to cell death by necrosis. However, the death process is difficult to observe due to the rapidity of the process and the reduced amount of inflammation. For these reasons, quantification of apoptosis is often difficult. A method of measuring the duration of the histologically visible stages of apoptosis (3 hours in normal rat liver) and a formula by which to calculate the cell loss rate by apoptosis is set forth by Bursch, et al.,
Carcinogenesis,
1990, 11, 847-853.
Evidence is also rapidly accumulating that growth factors and their receptors play a crucial role in the establishment and maintenance of transformed phenotypes. It is well established that growth factors play a crucial role in the establishment and maintenance of the transformed phenotype. Mouse embryo cells with a targeted disruption of IGF-IR genes cannot be transformed by SV40 T antigen and/or an activated Ha-ras oncogene that easily transform embryo cells generated from their wild-type littermates. Sell, et al.,
Proc. Natl. Acad. Sci. USA,
1993, 90, 11217-11221; Sell, et al.,
Mol. Cell. Biol.,
1994, 14, 3604-3612; Valentinis, et al.,
Oncogene,
1994, 9, 825-831; and Coppola, et al.,
Mol. Cell. Biol.,
1994, 14,, 4588-4595. Expression of an antisense RNA to the IGF-IR RNA in C6 rat glioblastoma cells not only abrogates tumorigenesis in syngeneic rats, but also causes complete regression of established wild type tumors. Resnicoff, et al.,
Cancer Res.,
1994a, 54, 2218-2222 and Resnicoff, et al.,
Cancer Res.,
1994b, 54, 4848-4850. Related to this finding is also the report by Harrington, et al. (
EMBO J.,
1994, 13, 3286-3295), that IGF-I (and PDGF) protect cells from c-myc induced apoptosis. A decrease in cell death rate in tumors could certainly be an important mechanism for tumor growth. Baserga,
The Biology of Cell Reproduction,
Harvard University Press, Cambridge, Mass., 1985. Cells expressing an antisense RNA to the IGF-IR RNA or cells pre-incubated with antisense oligonucleotides to the IGF-IR RNA completely lose their tumorigenicity when injected in either syngeneic or nude mice. Resnicoff et al., 1994a, 1994b. The injected cells were suspected of undergoing apoptosis or, at any rate, some form of cell death. Dying cells, however, are very difficult to demonstrate, because dying cells, especially in vivo, disappear very rapidly, and one is left with nothing to examine.
The importance of the IGF-IR in the control of cell proliferation is also supported by considerable evidence: 1) many cell types in culture are stimulated to grow by IGF-I (Goldring, et al.,
Crit. Rev. Eukaryot. Gene Expr.,
1991, 1, 301-326 and Baserga, et al.,
Crit. Rev. Eukaryot. Gene Expr.,
1993, 3, 47-61), and these cell types include human diploid fibroblasts, epithelial cells, smooth muscle cells, T lymphocytes, myeloid cells, chondrocytes, osteoblasts as well as the stem cells of the bone marrow; 2) interference with the function of the IGF-IR leads to inhibition of cell growth—which has been demonstrated using antisense expression vectors or antisense oligonucleotides to the IGF-IR RNA; the antisense strategy was successful in inhibiting cellular proliferation in several normal cell types and in human tumor cell lines (Baserga, et al., 1994, supra.); and 3) growth can also be inhibited using peptide analogues of IGF-I (Pietrzkowski, et al.,
Cell Growth
&
Diff.,
1992a, 3, 199-205 and Pietrzkowski, et al.,
Mol. Cell. Biol.,
1992b, 12, 3883-3889), or a vector expressing an antisense RNA to the IGF-I RNA (Trojan, et al., 1993, supra.). The IGF autocrine or paracrine loop is also involved in the growth promoting effect of other growth factors, hormones (for instance, growth hormone and estrogens), and oncogenes like SV40 T antigen and c-myb, and in tumor suppression, as in the case of WT1. Baserga, et al., 1994, supra. Inducing resistance to tumor growth is also disclosed in, for example, U.S. Pat. No. 5,714,170, which is incorporated herein by reference in its entirety. A review of the role of IGF-IR in tumors is provided in Baserga et al.,
Vitamins and Hormones,
1997, 53, 65-98, which is incorporated herein by reference in its entirety.
Testing agents such as, for example, growth factors and growth factor receptors for their ability to maintain or suppress transformed phenotypes remains difficult. In order to obtain an accurate account of the tumor suppressive ability, testing should be performed in vivo. The present invention provides a method of inducing resistance to or regression of tumor growth with markedly reduced side effects to the patient.
SUMMARY OF THE INVENTION
The present invention is directed to a method of inducing resistance to tumor growth in a human comprising contacting a tumor cell in vitro or ex vivo with an oligonucleotide complementary to IGF-IR, and implanting a diffusion chamber containing the treated tumor cell into the rectus sheath of the human for a therapeutically effective time, thereby inducing resistance to tumor growth.
The present invention is also directed to a method of inducing regression of a tumor in a human comprising contacting a tumor cell in vitro or ex vivo with an oligonucleotide complementary to IGF-IR, and implanting a diffusion chamber containing the treated tumor cell into the rectus sheath of the human for a therapeutically effective time, thereby inducing regression of the tumor.
REFERENCES:
patent: 4736866 (1988-04-01), Leder et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 5077059 (1991-12-01), Mishima et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5173414 (1992-12-01), Lebkowski et al.
patent: 5252479 (1993-10-01), Srivastava
patent: 5262308 (1993-11-01), Baserga
patent: 5272082 (1993-12-01), Santoli et al.
patent: 5354674 (1994-10-01), Hodgson
patent: 5354678 (1994-10-01), Lebkowski et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5460831 (1995-10-01), Kossovsky et al.
patent: WO 91/17253 (1991-11-01), None
patent: WO 92/22486 (1994-10-01), None
patent: WO 96/14746 (1996-05-01), None
patent: WO 97/18241 (1997-05-01), None
patent: WO 97/37010 (1997-10-01), None
patent: WO 99/23259 (1999-05-01), None
Restifo et al. (1993) J. Immunother., vol. 14, 182-190.*
Branch (1998) Antisense & Nucleic Ac
Abraham David
Andrews David W.
Baserga Renato L.
Resnicoff Mariana
Thomas Jefferson University
Wehbe' Anne M.
Woodcock & Washburn LLP
LandOfFree
Treatment of tumors with oligonucleotides directed to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of tumors with oligonucleotides directed to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of tumors with oligonucleotides directed to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3021540